Innoviva, Inc. 8-K
Earnings
Armata Pharmaceuticals’ share-price gains drove the swing to profit; product sales growth offset lower royalty revenue.
Filed 2026-05-06 16:19 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q1 2026 results, with growth in product sales offsetting lower gross royalty revenue. Net income was supported by favorable investment fair-value changes; the company also repurchased shares and expects NUZOLVENCE to become available in H2 2026.
Key Figures
| Metric | Q1 2026 | Q1 2025 | Y/Y |
|---|---|---|---|
| Total revenue | $98.0M | $88.6M | 11% |
| Income from operations | $38.2M | $41.4M | -8% |
| Net income (loss) | $187M | $(46.6)M | n/m |
| Diluted EPS | $2.22 | $(0.74) | n/m |
| Basic EPS | $2.52 | $(0.74) | n/m |
| Operating cash flow | $35.3M | $48.6M | -27% |
| Net product sales | $41.4M | $30.3M | 37% |
| Gross royalty revenue | $58.6M | $61.3M | -4% |
- Net product sales growth included $34.2M in U.S. sales, up 29% Y/Y; gross royalty revenue was lower.
- Net income reflected $191.2M in net favorable fair-value changes in equity method, equity and long-term investments, primarily from Armata Pharmaceuticals’ share-price appreciation.
- Cash and cash equivalents were $603.1M at 3/31/2026. Innoviva repurchased 971,066 shares for $20.4M during the quarter under its $125M program; cumulative repurchases were 1,198,921 shares for $25.0M.
Guidance
No guidance in this filing.
Investor Takeaways
- Watch for NUZOLVENCE availability in H2 2026 and subsequent IST sales performance.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3